Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation

Autor: Jerry W. Simecka, Riyaz Basha, Vadiraja B. Bhat, Robert W. Holloway, Ekamber Kariali, Liz Daniel, Susan B. Ingersoll, Umesh T. Sankpal, Sarfraz Ahmad, Jamboor K. Vishwanatha
Rok vydání: 2016
Předmět:
0301 basic medicine
Proteomics
Cell cycle checkpoint
Sp1 Transcription Factor
Survivin
Blotting
Western
Antineoplastic Agents
Apoptosis
Biology
Carcinoma
Ovarian Epithelial
Real-Time Polymerase Chain Reaction
Flow cytometry
Inhibitor of Apoptosis Proteins
03 medical and health sciences
0302 clinical medicine
Cell Movement
medicine
Biomarkers
Tumor
Tumor Cells
Cultured
Humans
ortho-Aminobenzoates
Neoplasms
Glandular and Epithelial
RNA
Messenger
Cell Proliferation
Cisplatin
Ovarian Neoplasms
Matrigel
medicine.diagnostic_test
Cell growth
Reverse Transcriptase Polymerase Chain Reaction
Anti-Inflammatory Agents
Non-Steroidal
Cell Cycle
General Medicine
Cell cycle
Molecular biology
030104 developmental biology
030220 oncology & carcinogenesis
Drug Therapy
Combination
Female
Reactive Oxygen Species
medicine.drug
Zdroj: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(10)
ISSN: 1423-0380
Popis: The expression of specificity protein 1 (Sp1) and survivin was evaluated in clinical specimens of epithelial ovarian cancer (EOC) patients. When compared to normal tissue, EOC samples showed high expression of Sp1 and survivin using qPCR (Sp1: ∼2-fold; survivin: ∼5-fold) and Western blot (Sp1: >2.6-fold; survivin: >100-fold). The Sp1 inhibitor, and anti-cancer small molecule, tolfenamic acid (TA), was tested to enhance the response of Cisplatin (Cis) in EOC cell lines. Cell viability (CellTiter-Glo), combination index (CalcuSyn software), apoptosis (Annexin-V staining), cell cycle analyses (flow cytometry), and reactive oxygen species (flow cytometry) were determined. Cell migration and invasion was assessed using matrigel coated transwell chambers. Agilent Technologies proteomics analysis identified potential signaling pathways involved. The combination of TA (50 μM) and Cis (5 μM) synergistically increased the growth inhibition in ES2 (∼80 %, p
Databáze: OpenAIRE
Externí odkaz: